Page 29 Volume 18 - N.1 - 2010

Dor (2010) 18
efeitos de desintoxicação para uma outra finalida- 10. Mellar P. Methadone for relief of cancer pain: a review of pharma-
de e oferecer, assim, aos doentes das unidades de cokinetics, pharmacodynamics, drug interactions and protocols of
administration. Support Care Cancer. 2001;9:73-83.
dor do SNS resposta personalizada adequada 11. Mercadante S. Methadone in cancer pain. Eur J Pain. 2001;1:77-85.
quando os analgésicos opióides convencionais 12. Ripamonti C, Bianchi M, Bruera E. Methadone: an orphan drug? J
não são eficazes, cumprindo as directivas que Palliat Med. 2004;7(1):73-4.
organismos internacionais, como a OMS e Pain 13. Mancini I, Lossignol DA, Body JJ. Opioid switch to oral methadone
in cancer pain. Curr Opin Oncol. 2000;12:308-13.
Relief Foundation, têm vindo a preconizar. 14. Lynch M. A review of the use of methadone for the treatment of
chronic non cancer pain. Pain Res Manage. 2005;10:3.
15. Manfredi P, Bianchi M. Prescribing methadone, a unique analgesic.
Bibliografia J Support Oncol. 2003;1:216-20.
16. Mercadante S. Rapid switching from morphine to methadone in
nd
1. World Health Organization. Cancer pain relief. 2 ed. World Health cancer patients with poor response to morphine. J Clin Oncol.
Organization. 1999. 1999;17:3307-12.
2. Bruera E, Palmer J, Bosnjak S, et al. Methadone versus morphine 17. De Stoutz ND, Bruera E, Suárez-Almazor M. Opioid rotation for
as a first line strong opioid for cancer pain: a randomized, double toxicity reduction in terminal cancer patients. J Pain Symptom Man-
blind study. J Clin Oncology. 2004;22(1):185-92. age. 1995;10:378-84.
3. Gagnon B, Bruera E. Differences in the ratios of morphine to meth- 18. Mercadante S. Opioid rotation in cancer pain: rationale and clinical
adone in patients with neuropathic pain versus non-neuropathic aspects. Cancer. 1999;86:1856-66.
pain. J Pain Symptom Manage. 1999;18:120-5. 19. Bruera E, Pereira J, Watanabe S, et al. Opioid rotation in patients
4. Leng G, Finnegan MJ. Successful use of methadone in nociceptive with cancer pain. Cancer. 1996;78(4):852-7.
cancer pain unresponsive to morphine. Palliat Med. 1994;8:153-5. 20. Bruera EB, Pereira J, Watanabe S, et al. Systemic opioid therapy for
5. Scholes C, Gonty N, Trotman L. Methadone titration in opioid resis- chronic cancer pain: practical guidelines for converting drugs and
tant cancer pain. Eur J Cancer Care. 1999;8:26-9. routes. Cancer. 1996;78:852-7.
6. Ripamonti C, Bianchi M. The use of methadone for cancer pain. 21. Morley J, Makin M. The use of methadone in cancer pain poor re-
Hematol Oncol Clin North Am. 2002;16(3):543-55. sponsive to other opioids. Pain Reviews. 1998;5:51-8.
7. Nauck F, Osgathe C, Dickerson ED. A German model for methadone 22. Esphani N, Palmer LJ, Shen L, et al. Patterns of outpatient opioid
conversion. Am J Hosp Palliat Care. 2002;18:200-2. prescribing at a comprehensive cancer center: the dramatic in-
8. Gannon C. The use of methadone in the care of the dying. Eur J crease in methadone prescribing for cancer pain over a 3-year
Palliative Care. 1997;4:152-8. period. Proc Am Soc Clin Oncol. 2003;22:790[abstract 3177].
a
9. Ripamonti C, Zecca E, Bruera E. An update on the clinical use of 23. Caseiro JM. Prontuário das unidades de dor portuguesas. 2. ed.
methadone for cancer pain. Pain. 1997;70:109-15. APED; 2005.

DOR

28